- Report
- August 2025
- 180 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- March 2025
- 150 Pages
Global
From €3397EUR$3,850USD£2,938GBP
€4280EUR$4,850USD£3,701GBP
- Report
- August 2025
- 188 Pages
Global
From €3971EUR$4,500USD£3,434GBP
- Report
- January 2025
- 343 Pages
Global
From €4235EUR$4,799USD£3,662GBP
- Report
- August 2025
- 192 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- June 2025
- 135 Pages
Global
From €2646EUR$2,999USD£2,289GBP
- Report
- May 2025
- 159 Pages
Global
From €4191EUR$4,750USD£3,625GBP
- Report
- November 2024
- 239 Pages
Global
From €3684EUR$4,175USD£3,186GBP
- Report
- June 2025
- 100 Pages
Global
From €5250EUR$5,950USD£4,541GBP
- Report
- September 2025
- 269 Pages
Global
From €5162EUR$5,850USD£4,465GBP
- Report
- June 2025
- 180 Pages
Global
From €5250EUR$5,950USD£4,541GBP
- Report
- August 2025
- 187 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 181 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 190 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 194 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 187 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 191 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 189 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 190 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 188 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP

In the landscape of vaccines, mRNA (messenger RNA) vaccines represent a novel technology that has garnered substantial attention for its role in rapid vaccine development. These vaccines operate by instructing cells to produce a protein that triggers an immune response without using a live virus. This innovative approach stands out for its ability to be developed and scaled up swiftly in response to infectious diseases, offering a flexible platform for vaccine creation. While traditional vaccine development may take years of research and testing, mRNA vaccines can be designed once the genetic information of a pathogen is known.
The adoption of mRNA vaccines has been driven by their potential to address a broad spectrum of diseases beyond just infectious agents. Research is being conducted into their applicability in treating and preventing cancers, genetic disorders, and autoimmune diseases. This expansion of mRNA technology into various medical domains has contributed to the diversification of the vaccine industry.
Several prominent companies are active in the mRNA vaccines market, shaping its trajectory with their research and development efforts. Notable firms include Moderna, Pfizer in collaboration with BioNTech, and CureVac. These companies have invested heavily in mRNA technology, leading to advances that have solidified their positions as key players in the pharmaceutical and biotechnology sectors. Show Less Read more